News | April 29, 2008

Minimally Invasive Endograft Outperforms Surgical Repair

April 30, 2008 - A new study indicates that use of the minimally invasive W.L. GORE TAG Thoracic Endoprosthesis to treat descending thoracic aneurysms appears to be superior to open surgical repair in anatomically suitable patients.

Investigator Ellen D. Dillavou, M.D., from the division of vascular surgery at the University of Pittsburgh Medical Center, said this is the first study to look at the long-term (five-year) outcomes of the two procedures. "Our researchers studied outcomes of the TAG endograft after its implantation in 140 patients compared to 94 patients who had similar aneurysms repaired by open surgery, between September 1999 and May 2001, as well as 51 more patients who were added in 2003 after revision of the endograft." The long-term follow-up of the multi-center device trial which took place at centers throughout the United States, is detailed in the May 2008 issue of the Journal of Vascular Surgery.

Follow-up consisted of patient visits, computed tomography scans and X-rays at one and six months, then annually for five years. "Initially and at five years, TAG patients had better results," said Dr. Dillavou. "At five years aneurysm-related mortality was 2.8 percent compared to 11.7 percent in open surgery patients, and major adverse events were 57.9 percent vs. 78.7 percent. Endoleaks in TAG patients decreased from 8.1 percent at one month to 4.3 percent at five years."

There were no aneurysm ruptures reported in either group over the study period and no deaths due to aneurysm-related causes after one year in either group. At five years, secondary procedures in the TAG group were lower (15.0 percent vs. 31.9 percent) and many were managed with a minimally invasive approach. Only five TAG patients underwent major aneurysm-related re-interventions (3.6 percent), including one arch aneurysm repair, one open aneurysm repair and three patients with minimally invasive procedures for endoleaks.

Dr. Dillavou added that at five years, aneurysm sac size decreased in 50 percent of the patients and increased in 19 percent of them, compared to the one-month baseline. Comparison with the modified low-porosity device at two years showed sac increase in 12.9 percent of original vs. 2.9 percent in modified grafts. "Although sac enlargement is concerning, early modified device results indicate this issue may be resolved," said Dr. Dillavou.

"Prior to this report it was not known if minimally invasive repairs would be as durable as traditional open repairs," said Dr. Dillavou. "This study demonstrates that in suitable patients, endovascular repair of thoracic aneurysms has clear and lasting advantages over open aneurysm repair and that the TAG endograft is durable to five years of follow-up. This work confirms that the early advantages of minimally invasive endovascular thoracic aneurysm repair extend to five years of follow-up. TAG patients had fewer deaths and complications from their aneurysms, making this the safest approach for suitable patients."

For more information: www.jvascsurg.org and www.VascularWeb.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init